Member Info for Jarv55

Think the costs are low here on the masks hopefully they can get some details on that out

Face Masks – 1000 boxes of 10 masks

£10,000.00 excluding vat

1000 boxes of 10 Anti-viral Face Mask with patented virucidal layer

5-ply BREATHABLE design certified to ISO 18184

• World’s first anti-COVID-19 face mask
• Kills viruses for Over 7 hours
• Includes patented virucidal layer certified to ISO 18184
• 5-ply BREATHABLE design
• Ideal PPE choice for Covid-19
– Bacterial Filtration efficiency 99.98%
– Anti-Influenza
– CE Certified to EN14683:2019
– designed and tested by UK university scientists
– Type IIR face mask
– Latex free, soft fibre material for a comfortable fit
– Integrated nose clip
– Soft, elastic ear loops
– Packaged in 10s or 50s
– Sterilised & Disposable

Delivery January 2021

Image is for illustration purposes only.

They are following the same path to Ncyt by advertising on their website that is how Ncyt started

let that sink in https://www.pharm2farm.org/product/face-masks-500-boxes-of-10-masks/

Hammer time https://invst.ly/sqsc3

Break out of the wedge may back test but expect to see Rms back at the highs https://invst.ly/sqrol

https://www.pharm2farm.org/shop/

https://www.lse.co.uk/rns/LOGP/holdings-in-company-vznpm1gcv3qvndu.html

Got to say this bb is very quiet considering we are nearing a JV

The Company has been notified that Paul Ryan, Non-Executive Chairman of the Company, has elected to convert his entire Convertible Loan Note ("CLN") which was issued on 24 July 2020 into ordinary shares. The CLN was for a principal amount of £35,334, has a conversion price of 0.28 pence and a 6% payment in kind coupon. Accordingly, Paul Ryan will be issued with 12,824,042 ordinary shares in the Company ("CLN Shares") in full settlement of the loan and associated interest.



At the same time, Paul Ryan has exercised warrants associated with the CLN representing 12,618,928 ordinary shares in the Company, at 0.28 pence per warrant ("Warrant Shares"). Paul Ryan has also sold 12,821,995 ordinary shares in the Company.



Following these transactions, Paul Ryan's shareholding in the Company will increase to 67,593,249 shares in the Company, representing 4.41% per cent. of the enlarged issued share capital and total voting rights of the Company.

He actually owns more

APunter can you dm me on twitter please @Jarvy55

If they have the patent which I doubt they need to rns it.

Mornignton incorrect its applied for a patent

added a few more

all the derampers busily buying

http://www.helium-one.com/wp-content/uploads/2020/11/20-11-04-02-Helium-One-Presentation_RTO_Verf_V1.pdf

Think what he is done is smart he made a lot of money sold to take up his warrants and gained more skin in the game for the future uplift. Its priced in now.

Rms should licence the tech to these https://www.prnewswire.co.uk/news-releases/daddybaby-protective-masks-certified-by-bsi-contributing-to-the-prevention-and-control-of-the-global-pandemic-823987075.html see how fast they can make masks

No confusion he slice profits and bought warrants Director Dealing, Conversion of CLN and Total Voting Rights

The Company has been notified that Paul Ryan, Non-Executive Chairman of the Company, has elected to convert his entire Convertible Loan Note ("CLN") which was issued on 24 July 2020 into ordinary shares. The CLN was for a principal amount of £35,334, has a conversion price of 0.28 pence and a 6% payment in kind coupon. Accordingly, Paul Ryan will be issued with 12,824,042 ordinary shares in the Company ("CLN Shares") in full settlement of the loan and associated interest.



At the same time, Paul Ryan has exercised warrants associated with the CLN representing 12,618,928 ordinary shares in the Company, at 0.28 pence per warrant ("Warrant Shares"). Paul Ryan has also sold 12,821,995 ordinary shares in the Company.



Following these transactions, Paul Ryan's shareholding in the Company will increase to 67,593,249 shares in the Company, representing 4.41% per cent. of the enlarged issued share capital and total voting rights of the Company.